
We are honored to have won Excellence in Oncology at the @Citeline Biotech Awards 2026. Our CEO @PaulPeterTak also received the Achiever of the Year award. Thank you to Citeline and the judges! citeline.com/awards/citeline… #CitelineBiotechAwards
✓Candel Therapeutics an off-the-shelf multimodal biological immunotherapy company empowering the patient's immune system to fight cancer.

We are honored to have won Excellence in Oncology at the @Citeline Biotech Awards 2026. Our CEO @PaulPeterTak also received the Achiever of the Year award. Thank you to Citeline and the judges! citeline.com/awards/citeline… #CitelineBiotechAwards

Today we reported our third quarter 2026 financial results. See the press release here: ir.candeltx.com/news-release…

We’re honored to be shortlisted in the Excellence in Oncology category at the @Citeline Biotech Awards 2026. Thank you to Citeline for the recognition! citeline.com/awards/citeline…

Last week, Candel joined LUNGevity’s Celebration of Hope and Progress in New York City. Proud to support @lungevity. Good to see @StermanDaniel, co-principal investigator of Candel’s phase 3 AURORA trial, and team from @NYULangone. #LCAM #AnyoneWithLungs

It’s #Movember, a time to start conversations about men’s health. We’re advancing an investigational viral immunotherapy for men with localized prostate cancer, and we’re grateful to the patients and families who make that work possible. candeltx.com/

Candel CEO @PaulPeterTak will join a fireside chat at the @Stifel 2026 Healthcare Conference! Details here: ir.candeltx.com/news-release… #Stifel #Biotech

We’re sharing new data from three posters at @sitcancer #SITC26. Aglatimagene showed immune activation in localized #ProstateCancer and #NSCLC, and linoserpaturev data show durable clinical outcomes in a subset of patients with recurrent #glioblastoma. ir.candeltx.com/news-release…

We’re attending @UrologyUS LUGPA’s Annual Meeting. Visit us at Booth 213 in the exhibit hall and at Booth 18 during the CME course to learn about our investigational aglatimagene program in localized #ProstateCancer. We look forward to seeing you in Chicago #LUGPA2026!

We’re presenting a late-breaking abstract at @sitcancer! @BaroneExpMed will present longitudinal immune profiling and biodistribution and shedding data from our phase 2 PrTK05 trial of aglatimagene in localized intermediate-risk #ProstateCancer. ir.candeltx.com/news-release… #SITC26

November is #LungCancerAwarenessMonth. 1 in 19 people will be diagnosed with lung cancer in their lifetime. Candel's phase 3 aglatimagene program has the potential to address unmet need in #NSCLC patients who progress after checkpoint inhibitors. We support @lungevity.

It’s Brain Tumor Awareness Week. Our linoserpaturev program targets recurrent high-grade glioma with next-generation replication-competent oncolytic HSV. We’re advancing a treatment option for challenging brain cancers. #BrainTumorAwareness

Our CEO @PaulPeterTak connected with Brad Loncar at @BiotechTV during the @HCWCO Annual Global Investment Conference about the path to BLA filing for aglatimagene in localized prostate cancer and our lung cancer program. biotechtv.com/post/candel-th… #BLA #ProstateCancer

Our Chief Scientific Officer @BaroneExpMed spoke with Zach Gobst on the Impactful Breakthroughs podcast about her journey to cancer immunotherapy, her "backpack theory" of continuous growth, and why patients must remain central to drug development. share.transistor.fm/s/3723ad…

October is National Healthy Lung Month. Our aglatimagene program targets unmet need in #NSCLC patients with progression despite checkpoint inhibitors. We recently initiated our global phase 3 AURORA trial to advance treatment options. candeltx.com/ #HealthyLungMonth

#ICYMI We’ve appointed Martine Zimmermann, to our board of directors. She brings 30+ years of regulatory affairs and quality experience across multiple stages of drug development. citybiz.co/article/901157/ca… #Leadership

We’re presenting at @sitcancer’s Annual Meeting in November. Two poster presentations on new data from our aglatimagene besadenovec program in non-small cell lung cancer and clinical findings from linoserpaturev in #glioblastoma. ir.candeltx.com/news-release… #SITC26 @baroneExpMed